Clinical trial
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV…
NCT00217672 · Translational Oncology Research International, Other · Completed
Key facts
| NCT number | NCT00217672 |
|---|---|
| Title | Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer |
| Official title | A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | University of California, Los Angeles |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, Docetaxel |
| Enrollment | 76 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Nov 1, 2010 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 5, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: